NASDAQ:CYTH Cyclo Therapeutics (CYTH) Stock Price, News & Analysis → Has Jeff Bezos Found the Next Nvidia? (From InvestorPlace) (Ad) Free CYTH Stock Alerts $1.26 -0.03 (-2.33%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.26▼$1.3550-Day Range$1.16▼$1.7652-Week Range$0.84▼$2.57Volume28,155 shsAverage Volume99,874 shsMarket Capitalization$36.19 millionP/E RatioN/ADividend YieldN/APrice Target$3.30 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cyclo Therapeutics alerts: Email Address Cyclo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside161.9% Upside$3.30 Price TargetShort InterestHealthy0.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector459th out of 915 stocksBiological Products, Except Diagnostic Industry70th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingCyclo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCyclo Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.47% of the float of Cyclo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclo Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclo Therapeutics has recently increased by 65.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCyclo Therapeutics does not currently pay a dividend.Dividend GrowthCyclo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYTH. Previous Next 2.3 News and Social Media Coverage News SentimentCyclo Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cyclo Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Cyclo Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders29.78% of the stock of Cyclo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.55% of the stock of Cyclo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclo Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclo Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclo Therapeutics has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHas Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…Click Here for Full Details About Cyclo Therapeutics Stock (NASDAQ:CYTH)Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.Read More CYTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTH Stock News HeadlinesApril 27, 2024 | americanbankingnews.comCyclo Therapeutics, Inc. (NASDAQ:CYTH) Sees Significant Increase in Short InterestApril 23, 2024 | americanbankingnews.comCyclo Therapeutics (NASDAQ:CYTH) Now Covered by Analysts at Ascendiant Capital MarketsApril 28, 2024 | InvestorPlace (Ad)Has Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…April 23, 2024 | nasdaq.comAscendiant Capital Initiates Coverage of Cyclo Therapeutics (CYTH) with Buy RecommendationApril 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)April 10, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics StockMarch 19, 2024 | investorplace.comCYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023March 18, 2024 | businesswire.comCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateApril 28, 2024 | InvestorPlace (Ad)Has Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…March 14, 2024 | finance.yahoo.comCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseMarch 14, 2024 | businesswire.comCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's DiseaseFebruary 2, 2024 | finance.yahoo.comCyclo Therapeutics, Inc. (CYTH)January 29, 2024 | markets.businessinsider.comCyclo Therapeutics Gets Notice Of Allowance For Patent Regarding Treatment Of Alzheimer's DiseaseJanuary 29, 2024 | finance.yahoo.comCyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark OfficeJanuary 3, 2024 | morningstar.comCyclo Therapeutics Inc CYTHDecember 28, 2023 | msn.comCytosorbents, Cyclo Therapeutics among healthcare moversDecember 18, 2023 | finance.yahoo.comCyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1December 14, 2023 | finance.yahoo.comRafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsNovember 29, 2023 | businesswire.comAPPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied ...November 21, 2023 | finance.yahoo.comCyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024November 15, 2023 | msn.comCyclo Therapeutics reports Q3 resultsNovember 15, 2023 | finance.yahoo.comCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 10, 2023 | seekingalpha.comWISH, REAL and PIXY among mid-day moversNovember 2, 2023 | finance.yahoo.comSeveral Insiders Invested In Cyclo Therapeutics Flagging Positive NewsOctober 30, 2023 | finance.yahoo.comRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsOctober 23, 2023 | finance.yahoo.comCyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 MillionOctober 5, 2023 | finance.yahoo.comCyclo Therapeutics to Present at 8th Annual Dawson James ConferenceSee More Headlines Receive CYTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CYTH CUSIPN/A CIK922247 Webwww.ctd-holdings.com Phone(386) 418-8060Fax321-244-8351Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$3.30 High Stock Price Target$4.00 Low Stock Price Target$2.60 Potential Upside/Downside+161.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,060,000.00 Net Margins-1,864.03% Pretax Margin-1,864.03% Return on Equity-4,506.97% Return on Assets-290.83% Debt Debt-to-Equity RatioN/A Current Ratio1.45 Quick Ratio1.42 Sales & Book Value Annual Sales$1.08 million Price / Sales33.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book6.00Miscellaneous Outstanding Shares28,720,000Free Float20,164,000Market Cap$36.19 million OptionableNo Data Beta-0.15 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. N. Scott Fine (Age 67)CEO & Director Comp: $569.92kMr. C. E Strattan (Age 78)Founder & Director Mr. Joshua M. Fine (Age 42)CFO & Secretary Comp: $421.17kMr. Michael Eric Lisjak (Age 50)Global Head of Regulatory Affairs & Senior VP of Business Development Comp: $430.4kDr. Jeffrey L. Tate Ph.D. (Age 66)COO, Chief Quality Officer & Director Comp: $255.14kMs. Lori McKennaGlobal Head of Patient AdvocacyDr. Karen Mullen FFPMInterim Chief Medical OfficerMore ExecutivesKey CompetitorsProtara TherapeuticsNASDAQ:TARABrainstorm Cell TherapeuticsNASDAQ:BCLIIN8bioNASDAQ:INABCortexymeNASDAQ:CRTXEstrella ImmunopharmaNASDAQ:ESLAView All CompetitorsInsiders & InstitutionsFounders Fund V Management LLCBought 480,708 shares on 2/15/2024Ownership: 2.115%Founders Fund VI Management LLCBought 110,023 shares on 2/15/2024Ownership: 0.484%Rafael Holdings, Inc.Bought 4,000,000 shares on 8/1/2023Total: $5 M ($1.25/share)View All Insider TransactionsView All Institutional Transactions CYTH Stock Analysis - Frequently Asked Questions Should I buy or sell Cyclo Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTH shares. View CYTH analyst ratings or view top-rated stocks. What is Cyclo Therapeutics' stock price target for 2024? 2 analysts have issued 12-month price objectives for Cyclo Therapeutics' stock. Their CYTH share price targets range from $2.60 to $4.00. On average, they predict the company's share price to reach $3.30 in the next twelve months. This suggests a possible upside of 161.9% from the stock's current price. View analysts price targets for CYTH or view top-rated stocks among Wall Street analysts. How have CYTH shares performed in 2024? Cyclo Therapeutics' stock was trading at $1.59 at the beginning of 2024. Since then, CYTH shares have decreased by 20.8% and is now trading at $1.26. View the best growth stocks for 2024 here. Are investors shorting Cyclo Therapeutics? Cyclo Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 75,300 shares, an increase of 65.1% from the March 31st total of 45,600 shares. Based on an average daily trading volume, of 106,700 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.5% of the company's stock are sold short. View Cyclo Therapeutics' Short Interest. When is Cyclo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CYTH earnings forecast. How were Cyclo Therapeutics' earnings last quarter? Cyclo Therapeutics, Inc. (NASDAQ:CYTH) released its quarterly earnings results on Monday, March, 18th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 4,506.97% and a negative net margin of 1,864.03%. How do I buy shares of Cyclo Therapeutics? Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTH) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
